BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21633861)

  • 1. Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases.
    El-Karaksy H; Fahmy M; El-Raziky M; El-Koofy N; El-Sayed R; Rashed MS; El-Kiki H; El-Hennawy A; Mohsen N
    World J Pediatr; 2011 Aug; 7(3):224-31. PubMed ID: 21633861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
    Zeybek AC; Kiykim E; Soyucen E; Cansever S; Altay S; Zubarioglu T; Erkan T; Aydin A
    Pediatr Int; 2015 Apr; 57(2):281-9. PubMed ID: 25223216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of NTBC after liver transplantation in tyrosinemia type 1.
    Kurihara K; Toyoda H; Amoano K; Inoue M; Uchida K; Sakurai H; Hayashi A; Hirayama M
    Pediatr Int; 2018 Nov; 60(11):1039-1041. PubMed ID: 30375135
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
    Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
    Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough?
    El-Karaksy H; Rashed M; El-Sayed R; El-Raziky M; El-Koofy N; El-Hawary M; Al-Dirbashi O
    Eur J Pediatr; 2010 Jun; 169(6):689-93. PubMed ID: 19882170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].
    Raimann E; Cornejo V; Arias C; Cabello JF; Castro G; Fernández E; de la Parra A
    Rev Med Chil; 2012 Feb; 140(2):169-75. PubMed ID: 22739945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1.
    Seda Neto J; Leite KM; Porta A; Fonseca EA; Feier FH; Pugliese R; Miura IK; Chapchap P; Porta G
    Pediatr Blood Cancer; 2014 Sep; 61(9):1584-9. PubMed ID: 24852359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Lithuanian Case of Tyrosinemia Type 1 with a Literature Review: A Rare Cause of Acute Liver Failure in Childhood.
    Rokaitė R; Čibirkaitė A; Zeleckytė V; Lazdinytė G; Dženkaitis M
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.
    Couce ML; Sánchez-Pintos P; Aldámiz-Echevarría L; Vitoria I; Navas V; Martín-Hernández E; García-Volpe C; Pintos G; Peña-Quintana L; Hernández T; Gil D; Sánchez-Valverde F; Bueno M; Roca I; López-Ruzafa E; Díaz-Fernández C
    Medicine (Baltimore); 2019 Sep; 98(39):e17303. PubMed ID: 31574857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early effect of NTBC on renal tubular dysfunction in hereditary tyrosinemia type 1.
    Maiorana A; Malamisura M; Emma F; Boenzi S; Di Ciommo VM; Dionisi-Vici C
    Mol Genet Metab; 2014 Nov; 113(3):188-93. PubMed ID: 25172236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
    Mayorandan S; Meyer U; Gokcay G; Segarra NG; de Baulny HO; van Spronsen F; Zeman J; de Laet C; Spiekerkoetter U; Thimm E; Maiorana A; Dionisi-Vici C; Moeslinger D; Brunner-Krainz M; Lotz-Havla AS; Cocho de Juan JA; Couce Pico ML; Santer R; Scholl-Bürgi S; Mandel H; Bliksrud YT; Freisinger P; Aldamiz-Echevarria LJ; Hochuli M; Gautschi M; Endig J; Jordan J; McKiernan P; Ernst S; Morlot S; Vogel A; Sander J; Das AM
    Orphanet J Rare Dis; 2014 Aug; 9():107. PubMed ID: 25081276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?
    Koelink CJ; van Hasselt P; van der Ploeg A; van den Heuvel-Eibrink MM; Wijburg FA; Bijleveld CM; van Spronsen FJ
    Mol Genet Metab; 2006 Dec; 89(4):310-5. PubMed ID: 17008115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The outcome of seven patients with hereditary tyrosinemia type 1.
    Gokay S; Ustkoyuncu PS; Kardas F; Kendirci M
    J Pediatr Endocrinol Metab; 2016 Oct; 29(10):1151-1157. PubMed ID: 27682708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosinemia type I: Case series with response to treatment to NTBC.
    Shah I; Shah F
    Indian J Gastroenterol; 2016 May; 35(3):229-31. PubMed ID: 27109516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Québec NTBC Study.
    ; Alvarez F; Atkinson S; Bouchard M; Brunel-Guitton C; Buhas D; Bussières JF; Dubois J; Fenyves D; Goodyer P; Gosselin M; Halac U; Labbé P; Laframboise R; Maranda B; Melançon S; Merouani A; Mitchell GA; Mitchell J; Parizeault G; Pelletier L; Phan V; Turcotte JF
    Adv Exp Med Biol; 2017; 959():187-195. PubMed ID: 28755196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary Tyrosinemia Type 1 in Turkey.
    Aktuglu-Zeybek AC; Kiykim E; Cansever MS
    Adv Exp Med Biol; 2017; 959():157-172. PubMed ID: 28755194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
    Kienstra NS; van Reemst HE; van Ginkel WG; Daly A; van Dam E; MacDonald A; Burgerhof JGM; de Blaauw P; McKiernan PJ; Heiner-Fokkema MR; van Spronsen FJ
    J Inherit Metab Dis; 2018 Mar; 41(2):181-186. PubMed ID: 29170874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1-fetoprotein normalization.
    Bhushan S; Noble C; Balouch F; Lewindon P; Lampe G; Hodgkinson P; McGill J; Ee L
    Pediatr Transplant; 2022 Nov; 26(7):e14334. PubMed ID: 35698261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosinemia Type I in Japan: A Report of Five Cases.
    Nakamura K; Ito M; Shigematsu Y; Endo F
    Adv Exp Med Biol; 2017; 959():133-138. PubMed ID: 28755191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation.
    Joshi SN; Venugopalan P
    Ann Trop Paediatr; 2004 Sep; 24(3):259-65. PubMed ID: 15479577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.